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Abstract In human embryonic kidney cells over-expressing the
human vanilloid receptor type 1 (VR1), palmitoylethanolamide
(PEA, 0.5^10 WM) enhanced the effect of arachidonoylethanol-
amide (AEA, 50 nM) on the VR1-mediated increase of the
intracellular Ca2+ concentration. PEA (5 WM) decreased the
AEA half-maximal concentration for this effect from 0.44 to
0.22 WM. The PEA effect was not due to inhibition of AEA
hydrolysis or adhesion to non-specific sites, since bovine serum
albumin (0.01^0.25%) potently inhibited AEA activity, and PEA
also enhanced the effect of low concentrations of the VR1
agonists resiniferatoxin and capsaicin. PEA (5 WM) enhanced the
affinity of AEA for VR1 receptors as assessed in specific binding
assays. These data suggest that PEA might be an endogenous
enhancer of VR1-mediated AEA actions. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Anandamide (arachidonoylethanolamide, AEA) was the
¢rst endogenous substance to be proposed as a cannabinoid
receptor ligand in 1992 [1]. Yet, AEA belongs to a family of
lipids known since the late 1950s, the N-acylethanolamines
(reviewed in [2]), which also includes the anti-in£ammatory
compound palmitoylethanolamide (PEA). Recently there has
been renewed interest in the properties of PEA ([3], and [4] for
review), and it was proposed that this lipid could act as an
agonist for the cannabinoid receptor type 2 (CB2) [5]. How-
ever, PEA exhibits very little, if any, a⁄nity for the cloned
CB1 and CB2 cannabinoid receptors from rat, mouse or man
[6^8]. The hypothesis that this compound owes its properties
to CB2-like cannabinoid receptors, proposed by some authors
to explain why PEA analgesic e¡ects were antagonized by a
CB2 receptor blocker [9,10], has not found any molecular
support to date. Other authors have suggested that PEA
may act as an ‘entourage’ compound, i.e. by inhibiting the
inactivation of endogenous cannabinoids such as AEA, there-
by increasing their levels [4]. However, although PEA is hy-
drolyzed by the enzyme mostly responsible for AEA degrada-
tion, the fatty acid amide hydrolase (FAAH, see [11] for a
recent review), this compound is not a very e⁄cacious inhib-
itor of AEA hydrolysis [12]. A recent study showed that,
rather than directly inhibiting AEA hydrolysis by substrate
competition, PEA a¡ects the degradation of AEA by down-
regulating the expression of FAAH [13]. PEA is co-synthe-
sized with AEA in most of the cells analyzed so far in
amounts 5^10-fold higher [4,14], and could thus play a role
as an ‘entourage’ substance for AEA when the two substances
are endogenously produced.
A possibility that could explain some of the anti-in£amma-
tory and analgesic properties of PEA is that this compound
interacts with and immediately desensitizes a particular type of
nociceptor expressed in most peripheral C-¢bers, the type 1
vanilloid receptors (VR1), which are activated by protons,
heat and plant toxins such as capsaicin and resiniferatoxin
(RTX) [15]. Although leading to painful responses and local
vasodilation, activation of these receptors is immediately fol-
lowed by desensitization, so that they become refractory to
subsequent stimulation by nociceptive stimuli. Therefore,
some VR1 ligands have been used paradoxically to induce
analgesia and inhibit in£ammation [16]. AEA was recently
found to fully activate, and subsequently desensitize, both rat
and human VR1, although at concentrations 5^20-fold higher
than those necessary for capsaicin to exert the same action, or
for AEA to activate CB1 receptors [17,18]. However, several
regulatory events are being found that render AEA equipotent
at VR1 and CB1 receptors [19^21] and, hence, a potential
‘endovanilloid’ [22]. Here we investigated the possibility that
PEA, previously shown to exert per se only a negligible e¡ect
on VR1 even at high concentrations [18,23], enhances the po-
tency of AEA at this receptor, thus possibly behaving as an
endogenous modulator of endovanilloid activity.
2. Materials and methods
2.1. Materials and cells
AEA and PEA were synthesized from arachidonic acid or palmitic
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acid and ethanolamine, as described in [1], whereas RTX and capsai-
cin were purchased from Calbiochem. Fatty acid-free bovine serum
albumin (BSA) was from Sigma. Over-expression of human VR1
cDNA into human embryonic kidney (HEK) 293 cells was carried
out as described previously [24]. Cells were grown as monolayers in
minimum essential medium supplemented with non-essential amino
acids, 10% fetal calf serum and 0.2 mM glutamine, and maintained
under 95% O2/5% CO2 at 37‡C.
2.2. Intracellular Ca2+ assay
The e¡ect of the substances on intracellular Ca2 concentration
([Ca2]i) was determined using Fluo-3, a selective intracellular £uo-
rescent probe for Ca2 [18,23]. One day prior to experiments cells
were transferred into six-well dishes coated with poly-L-lysine (Sigma)
and grown in the culture medium mentioned above. On the day of the
experiment the cells (50^60 000 per well) were loaded for 2 h at 25‡C
with 4 WM Fluo-3 methyl ester (Molecular Probes) in dimethyl sulf-
oxide containing 0.04% Pluronic. After the loading, cells were washed
with Tyrode pH 7.4, trypsinized, resuspended in Tyrode and trans-
ferred to the cuvette of the £uorescence detector (Perkin-Elmer
LS50B) under continuous stirring. Experiments were carried out by
measuring cell £uorescence at 25‡C (Vex = 488 nm, Vem = 540 nm) be-
fore and after the addition of the test compounds at various concen-
trations. Capsazepine (10 WM) was added 30 min before AEA. PEA
was added 5 min before AEA, RTX or capsaicin. Either a single
concentration of PEA before varying concentrations of the VR1 li-
gands, or varying concentrations of PEA before a sub-threshold con-
centration of the ligands, was tested. Data are expressed as the con-
centration exerting a half-maximal e¡ect (EC50). The e⁄cacy of the
e¡ect was determined by comparing it to the analogous e¡ect ob-
served with 4 WM ionomycin.
2.3. VR1 receptor binding assays
The a⁄nity of AEA for human VR1 receptors was assessed by
means of displacement assays carried out with membranes (50 Wg/
tube) from HEK-hVR1 cells, prepared as described previously [25]
but in the absence of FAAH inhibitors, and the high a⁄nity VR1
ligand [3H]RTX (48 Ci/mmol, NEN-Dupont), using the incubation
conditions described previously [25]. Under these conditions the Kd
and Bmax for [3H]RTX were 0.5 nM and 1.39 pmol/mg protein. The Ki
for the displacement of 1 nM [3H]RTX by increasing concentrations
of AEA, in the presence or absence of PEA 5 WM, was calculated
from the IC50 values (obtained by GraphPad Software) using the
Cheng^Pruso¡ equation. Speci¢c binding was calculated with 1 WM
RTX (Alexis Biochemicals) and was 78.1 þ 3.7%.
2.4. AEA hydrolase activity assays
HEK-hVR1 cells were cultured as described above. The e¡ect of
PEA (5 WM) on the enzymatic hydrolysis of AEA was studied as
described previously [20] by using cell membranes incubated with
either of the two compounds and [14C]AEA (9 WM) in 50 mM Tris^
HCl, pH 9, for 30 min at 37‡C. [14C]Ethanolamine produced from
[14C]AEA hydrolysis was measured by scintillation counting of the
aqueous phase after extraction of the incubation mixture with 2 vol-
umes of CHCl3/CH3OH 2:1 (v/v).
3. Results and discussion
In agreement with previous studies [18,20,21,23], AEA in-
duced a dose-dependent (EC50 = 0.44 þ 0.11 WM) increase in
[Ca2]i in HEK-hVR1 cells, which was blocked by capsaze-
pine and was absent in wild-type HEK cells (not shown). PEA
(0.5^10 WM), incubated with cells 5 min prior to AEA (50
nM), dose-dependently (estimated EC50V0.7 WM) enhanced
the e¡ect of the latter compound from 9.2 þ 4.4 to 24.6 þ 4.5%
of the e¡ect of 4 WM ionomycin (Fig. 1A). PEA alone also
induced a response, which was, however, negligible compared
to that observed with similar doses of AEA alone (up to
13.3 þ 3.2% of the e¡ect of ionomycin with 10 WM PEA,
mean þ S.E.M., n = 10), and had returned to baseline when
AEA was added to the cells after PEA pretreatment (not
shown). When increasing concentrations of AEA were tested
after PEA (5 WM), the half-maximal concentration of the for-
mer compound for the stimulation of [Ca2]i was decreased
from 0.44 to 0.22 WM (Fig. 1B). The e¡ect of PEA was more
marked, and statistically signi¢cant, only with concentrations
of AEA 6 0.25 WM, i.e. at concentrations at least 20-fold
lower than the concentration of PEA used, which re£ects to
some extent the molar ratio at which PEA and AEA are
found in most tissues.
We next wanted to determine if the e¡ect of PEA was due
to inhibition of AEA enzymatic hydrolysis. In fact, it has been
previously shown that degradation, very probably by FAAH,
signi¢cantly minimizes AEA activity at VR1 [20,25], and that
HEK-hVR1 cells do express FAAH and can hydrolyze AEA
[20]. However, no e¡ect was found here of PEA on the hy-
drolysis of [14C]AEA by HEK-hVR1 cell membranes (not
shown). Nevertheless, we decided to investigate if the en-
hancement of AEA-induced activation of hVR1 could also
be observed with other VR1 ligands, i.e. RTX and capsaicin.
These compounds, while being several-fold more potent than
AEA on VR1, are not substrates for FAAH and their e¡ect
Fig. 1. E¡ect of PEA on the VR1-mediated stimulation of [Ca2]i
by AEA in HEK-hVR1 cells. A: E¡ect of increasing concentrations
of PEA on the e¡ect of 50 nM anandamide. B: E¡ect of 5 WM
PEA on the e¡ect of varying concentrations of AEA. PEA was pre-
incubated with cells 5 min prior to AEA treatment. The e¡ect was
measured as the % of the e¡ect on [Ca2]i of 4 WM ionomycin.
Data are means þ S.D. of three separate determinations. *P6 0.05;
**P6 0.01, unpaired Student’s t-test.
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on [Ca2]i is insensitive to inhibitors of AEA hydrolysis
[20,25]. Indeed, we found that, when using concentrations of
RTX 6 4 pM, and of capsaicin 6 2 nM, PEA (5 WM) also
signi¢cantly enhanced the e¡ect of these two potent VR1 ag-
onists (Table 1). Interestingly, the e¡ect was more marked
with RTX than with capsaicin. It is noteworthy that for
many years it was believed that distinct binding sites existed
for these two compounds [16], but recent data have ruled out
this possibility [26]. However, it is likely that RTX and cap-
saicin interact with di¡erent amino acid residues within the
ligand binding site of VR1. Although these data rule out the
participation of FAAH in PEA-induced enhancement of VR1
ligand activity, we cannot exclude that other ‘entourage’ com-
pounds [27] that are better substrates for the enzyme, such as
oleoylethanolamide or linoleoylethanolamide, or oleamide,
also potentiate AEA activity at vanilloid receptors. Prelimi-
nary studies carried out in our laboratories seem to indicate
that this might be the case.
We also wanted to ascertain that PEA was not enhancing
AEA action by merely preventing this compound from bind-
ing to the cuvette used for the £uorimetric analysis. Therefore,
we assayed the e¡ect on AEA-induced increase of [Ca2]i of
BSA, which is normally used to avoid lipophilic substances
from sticking to plastic and glass ware. We were surprised to
¢nd that BSA did not enhance but instead potently inhibited
the AEA e¡ect on hVR1 (Fig. 2). This ¢nding can be ex-
plained by suggesting that BSA prevents the uptake of AEA
by HEK-hVR1 cells, thus interfering with the carrier-medi-
ated internalization of this compound, which is necessary to
observe activation of an intracellular hVR1 site by AEA [20].
Indeed, previous studies have shown that BSA is necessary to
observe AEA release from cells because otherwise this com-
pound is immediately taken up from the incubation medium
[28]. These data rule out the possibility that PEA enhance-
ment of AEA action on VR1 is due to inhibition of binding to
non-speci¢c sites, and explains why a potency 5^10-fold lower
than that reported by us ([19,20,23] and this study) has been
observed for AEA on VR1 by other authors [18,25,29] who all
introduced BSA in their VR1 assay protocols.
Finally, we investigated if the PEA e¡ect was due to en-
hancement of AEA binding to VR1. We studied the e¡ect of
PEA (5 WM) on AEA displacement of [3H]RTX from mem-
branes from HEK-hVR1 cells and found a decrease of the Ki
of AEA from 18.8 to 3.9 WM (Fig. 3). In this case, the dose^
response curve of AEA was shifted leftwards, suggesting that
PEA might act as an allosteric factor for AEA binding to
hVR1, and that this e¡ect may be responsible, at least in
part, for PEA-induced enhancement of the AEA e¡ect on
[Ca2]i. We were not surprised to observe a high Ki value
for the displacement of [3H]RTX by AEA, since Ross et al.
[25] have reported an even higher value when using mem-
branes from CHO cells over-expressing the rat VR1 in the
absence of AEA hydrolysis inhibitors.
In conclusion, we have shown here that PEA can signi¢-
cantly enhance the VR1-mediated action of AEA on [Ca2]i.
This e¡ect was not due to inhibition of AEA hydrolysis or of
AEA binding to non-speci¢c sites during the experiments, but
more likely to stimulation of AEA interaction with a RTX
Table 1
E¡ect of PEA on the VR1-mediated stimulation of [Ca2]i by low
doses of RTX and capsaicin in HEK-hVR1 cells
Substance % e¡ect of ionomycin (4 WM)
RTX 1 pM 9.8 þ 2.3
PEA 0.01 WM+RTX 1 pM 10.9 þ 4.1
PEA 0.05 WM+RTX 1 pM 14.8 þ 2.1*
PEA 0.1 WM+RTX 1 pM 15.2 þ 3.9*
PEA 1 WM+RTX 1 pM 23.0 þ 3.5**
PEA 5 WM+ RTX 1 pM 23.5 þ 4.9**
PEA 10 WM+RTX 1 pM 26.5 þ 5.1**
RTX 2 pM 16.1 þ 3.0
PEA 5 WM+RTX 2 pM 34.0 þ 7.2**
RTX 4 pM 33.9 þ 3.1
PEA 5 WM+ RTX 4 pM 44.9 þ 4.1*
Capsaicin 1 nM 7.6 þ 1.2
PEA 1 WM+capsaicin 1 nM 14.1 þ 1.2*
Capsaicin 4 nM 11.9 þ 3.1
PEA 1 WM+capsaicin 4 nM 23.1 þ 3.2**
PEA was preincubated with cells 5 min prior to RTX and capsaicin
treatment. The e¡ect was measured as the % of the e¡ect on [Ca2]i
of 4 WM ionomycin. For capsaicin, only the doses of PEA and cap-
saicin that yielded maximal enhancement are shown. Data are
means þ S.D. of three separate determinations. *P6 0.05; **P6 0.01,
unpaired Student’s t-test.
Fig. 2. E¡ect of BSA on the VR1-mediated stimulation of [Ca2]i
by AEA in HEK-hVR1 cells. The e¡ect of increasing concentrations
of BSA was assessed on two concentrations of AEA. BSA was pre-
incubated with cells 5 min prior to AEA treatment. Data are means
of three separate determinations. S.D. bars are not shown for the
sake of clarity.
Fig. 3. E¡ect of PEA on the displacement by AEA of [3H]RTX
from HEK-hVR1 cell membranes. Data are means þ S.D. of three
separate determinations.
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binding site within hVR1. Nevertheless, the e¡ect reported
here can still be described as an ‘entourage’ [4,27] action in-
asmuch as it was observed at molar ratios of AEA and PEA
(from 1:10 to 1:50) similar to those found in tissues and cells
(usually from 1:5 to 1:20). Likewise, 2-palmitoylglycerol was
shown to enhance the e¡ects on cannabinoid receptors of the
other endocannabinoid 2-arachidonoylglycerol without inhib-
iting its inactivation by cells [30]. It is possible that, by inter-
acting directly with VR1, PEA also enhances other known
biological e¡ects of VR1 ligands. Indeed, we have found (D.
Melck and V. Di Marzo, unpublished results) that PEA sig-
ni¢cantly potentiates the antiproliferative action of capsaicin
and RTX on human breast cancer cells, an e¡ect that was
previously reported to be counteracted by the VR1 blockers
capsazepine and ruthenium red [31].
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